Psoriatic Arthritis
Latest News
Study links air pollution to psoriasis flares
The findings underscore the need for clinicians to “consider environmental/external triggers in patients with chronic inflammatory diseases...
From the Journals
CV risk biomarkers tentatively identified in psoriatic disease
Troponin I and NT-proBNP levels were linked to cardiovascular risk independently of the Framingham Risk Score.
From the Journals
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
From the Journals
Methotrexate plus leflunomide proves effective for PsA
The combination therapy outperformed methotrexate monotherapy as a treatment option for patients with psoriatic arthritis (PsA), though it did...
From the Journals
One-third of psoriatic arthritis patients could have metabolic syndrome, data analysis finds
The results highlight the need for proper assessment of body weight and cardiovascular risk factors in patients with PsA at the onset of disease...
Commentary
An Update on JAK Inhibitors in Skin Disease
In this editorial, we focus on recent trials of JAK inhibitors tested in patients with atopic dermatitis, including topical RUX, as well as oral...
Conference Coverage
Guselkumab controls axial involvement in PsA through 2 years
In psoriatic arthritis patients with axial involvement, researchers saw sustained improvement with guselkumab through 100 weeks on all outcomes...
Latest News
How to make the most of your time with psoriasis patients
Patients have a long-term battle to get clear, and spending a little longer on the initial visit “pays a lot of dividends.”
Case Reports
Severe Acute Systemic Reaction After the First Injections of Ixekizumab
Acute onycholysis (within 72 hours) is a rare side effect of ixekizumab.
Latest News
A dermatologist-led model for CVD prevention in psoriasis may be feasible
The researchers see their findings as an early but promising step in finding better models to improve cardiovascular outcomes for patients with...
News from the FDA/CDC
FDA approves risankizumab (Skyrizi) for psoriatic arthritis
The approval is the second indication for the anti–interleukin-23 monoclonal antibody after clearance for plaque psoriasis was granted in 2019.